# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis maintains XOMA Royalty (NASDAQ:XOMA) with a Buy and raises the price target...
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick diseas...
HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.
XOMA (NASDAQ:XOMA) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.81) by 6.1...